Sumitomo Mitsui Trust Group
ABCL icon

Sumitomo Mitsui Trust Group’s AbCellera Biologics ABCL Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-62,759
Closed -$186K – 1054
2024
Q2 		$186K Hold
62,759
– – ﹤0.01% 1053
2024
Q1 		$284K Hold
62,759
– – ﹤0.01% 1081
2023
Q4 		$358K Hold
62,759
– – ﹤0.01% 1069
2023
Q3 		$289K Buy
62,759
+15,870
+34% +$96.5K ﹤0.01% 1091
2023
Q2 		$303K Hold
46,889
– – ﹤0.01% 1094
2023
Q1 		$354K Hold
46,889
– – ﹤0.01% 1095
2022
Q4 		$475K Buy
46,889
+4,053
+9% +$46.8K ﹤0.01% 1109
2022
Q3 		$424K Buy
+42,836
New +$470K ﹤0.01% 1136

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sumitomo Mitsui Trust Group's ABCL Position: Q3 2024 in Review

Sumitomo Mitsui Trust Group sold out of AbCellera Biologics (ABCL) in Q3 2024, closing a stake of 62,759 shares — an estimated $186K sold.

Sumitomo Mitsui Trust Group first reported a position in ABCL in Q3 2022 and held it in 8 quarters. The position peaked at $475K in Q4 2022. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

  • Sumitomo Mitsui Trust Group reported no remaining AbCellera Biologics position as of Q3 2024 after selling out during the quarter.
  • Sumitomo Mitsui Trust Group sold 62,759 AbCellera Biologics shares in Q3 2024, an estimated $186K.
  • Sumitomo Mitsui Trust Group first reported a position in AbCellera Biologics in Q3 2022 and held it in 8 quarters.
  • Sumitomo Mitsui Trust Group's AbCellera Biologics position peaked at $475K in Q4 2022.
  • 139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q3 2024, filed 5 Nov 2024.